The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•12 April 2026•

1 min read

Raymond James Upgrades PTC Therapeutics to 'Moderate Buy' Despite Earnings Miss

Key Facts

1Raymond James Financial upgraded PTC Therapeutics stock rating to 'moderate buy'.

2The company reported an EPS loss of $1.67, significantly worse than the expected $0.21 loss.

Raymond James Financial has upgraded PTC Therapeutics (PTCT) to a 'moderate buy' rating, signaling confidence in the biotech firm's prospects despite recent financial headwinds. This upgrade comes as the company reported a significant earnings miss, with an EPS loss of $1.67 compared to the anticipated $0.21 loss. Revenue for the quarter also fell short of expectations, declining 22.7% year-over-year to $164.7 million against a forecast of $281.5 million. Adding to the complexity, recent filings show that company insiders, including the CEO, sold approximately $8.5 million worth of shares over the last quarter. Investors are now weighing the positive analyst sentiment against the backdrop of weak financial performance and insider selling activity. These contrasting signals suggest potential volatility for PTCT shares as the market processes the divergent data points.